Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Amgen to acquire Horizon Therapeutics for US$26.4 Billion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 12, 2022 12:25pm

161 Views

Post# 35166331

RE:RE:RE:Amgen to acquire Horizon Therapeutics for US$26.4 Billion

Horizon Therapeutics has been primarily a "Generics Drug" company until recently when it developed a proprietary drug line in specialty products focusing on immunology.

ONCY is a proprietary drug company with a focus on immuno- oncology. (immunology/oncology).

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles